The Department of Health has asked the Institute to conduct an appraisal of rociletinib for previously treated locally advanced or metastatic, EGFR T790M -positive non-small-cell lung cancer. We have now been informed by the company that it will no longer be pursuing a licensing application , therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process STA
ID number 883

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 May 2016 Suspended, The Department of Health has asked the Institute to conduct an appraisal of rociletinib for previously treated locally advanced or metastatic, EGFR T790M -positive non-small-cell lung cancer. We have now been informed by the company that it will no longer be pursuing a licensing application , therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
22 March 2016 Draft scope documents
15 March 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance